H.C. Wainwright analyst Matthew Caufield raised the firm’s price target on Kodiak Sciences (KOD) to $38 from $26 and keeps a Buy rating on the shares. The firm upped its probability of success from 25% to 35% for tarcocimab and KSI-501 in wet age-related macular degeneration leading up to the Phase 3 DAYBREAK readout in Q3.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KOD: